Biomedical & Biotech News
Clinical progress, drug development, platform technologies, and regulatory moves.
An oral drug could become another treatment option for children with achondroplasia. A Phase 3 trial showed improved growth velocity, with changes in body proportions also observed in younger children; whether these results can deliver long-term health benefits remains an important question beyond the review.
Nature Medicine has published a cross-task evaluation of MedGemma, showing that training on medical data can improve image interpretation and reasoning performance. The core findings were made public last year and have now been published following peer review; each intended use still requires validation before application in patient care.
Disease control lasted slightly longer in the higher-dose group than with chemotherapy, but the difference was not statistically significant. Whether the signal of tumor shrinkage translates into longer survival remains to be answered by subsequent data.
A study covering 683 urine samples moves liquid biopsy from finding signs of cancer toward identifying treatment response and residual disease. The results open up new possibilities for monitoring, but whether they can improve actual care still requires validation in prospective trials.
Signals that promote lymphatic vessel formation may be further amplified after receptors pair up. A South Korean research team has analyzed protein structures and identified the key to clustering between complexes. The findings offer a research direction for regulating lymphatic vessel growth, but have not yet been shown to treat lymphedema or inhibit cancer metastasis.
In a 59-patient trial, samuraciclib combined with endocrine therapy showed higher rates of disease control; the signal was stronger in patients with no detected TP53 mutations, but the small sample size and gastrointestinal side effects remain questions that the next stage of research must address.
From building new companies to supporting later-stage development, Forbion’s latest fundraising is expected to support about 30 biotech companies. Investment has already begun, but whether the scale of the fundraising translates into new therapies still depends on the progress of individual development programs.
Blood tests and years of medical records may contain early signals of pancreatic cancer risk. Mayo Clinic’s updated retrospective analysis extends its exploration to five years before diagnosis, but prospective research is still needed to determine whether these findings can guide testing and improve patient outcomes.
Can delivering a drug into lesions control disease while preserving oral tissue? A small cohort in the Phase 2 trial of PRV111 has reported positive results, but the absence of abnormal cells in biopsy samples is still a long way from proving long-term efficacy and replacing surgery.
Differences in the abundance of certain proteins on cancer cell surfaces could offer an entry point for immunotherapy. A Heidelberg team used MPZL1 to direct CAR-T cells against multiple types of cancer cells, but normal tissues may also carry this marker, making safety in humans a key challenge.
How far is generative AI from being a reliable clinical assistant when making diagnoses from images and medical histories? A new study finds that response format and input information affect performance, while average results across studies are insufficient to establish whether it is safe to use in clinical practice.
A small test suggests that integrating ECGs and blood biomarkers could reduce false alarms in rejection monitoring. But whether biopsies can safely be avoided still depends on confirming that the model does not miss patients who need treatment.
After PARP inhibitors fail, do cancer cells still have vulnerabilities that can be targeted? ORIC-259 aims to weaken tumor survival by degrading CIP2A messenger RNA; a new collaboration will arrange the first human testing of this preclinical concept.